Logos Global Management LP — 13F Holdings

2026 Q3  ·  96 Positions

2026 Q3 Portfolio Activity

In 2026 Q3, Logos Global Management LP maintained a portfolio of 96 distinct positions. The most significant new addition was MADRIGAL PHARMACEUTICALS INC, now representing 2.71% of the total fund value. They heavily accumulated shares in PRAXIS PRECISION MEDICINES I, increasing the position by 63.5%. The fund also reduced its exposure to ERASCA INC by 79.4%.
Position History hover any row below to update
Loading…
PCA Score Concentration Risk
Risk ENB
Total Positions
96
Quarter
2026 Q3
Top Holding
PRAX (6.7%)
Top 10 Concentration
44.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 96

Logos Global Management LP Full Holdings List — 2026 Q3

Stock History Sector / Type Port % Prev % Rank / Prev Conviction
Freshness
Change % Change Influence Shares Mkt Value Avg Cost Price Held 1st Owned Source Source Date Date Reported
PRAX
PRAXIS PRECISIO...
Healthcare 6.67% 3.75% #1 7
Prev: #8
7.7
—
165,000 63.5%
P
S
425,000 $123,772,750 2024 Q1 13F Filing 2026-09-30 2026-11-16
RVMD
REVOLUTION MEDI...
Healthcare 6.63% 5.64% #2 1
Prev: #3
4.7
—
-100,000 -14.3%
P
S
600,000 $123,156,000 2020 Q1 13F Filing 2026-09-30 2026-11-16
IDYA
IDEAYA BIOSCIEN...
Healthcare 5.90% 4.81% #3 1
Prev: #4
3.9
—
-150,000 -5.0%
P
S
2,850,000 $109,497,000 2021 Q3 13F Filing 2026-09-30 2026-11-16
ERAS
ERASCA INC
Healthcare 4.66% 9.58% #4 3
Prev: #1
2.4
—
-6,250,000 -51.4%
P
S
5,900,000 $86,494,000 2024 Q2 13F Filing 2026-09-30 2026-11-16
ABVX
ABIVAX SA
Healthcare 4.64% 5.87% #5 3
Prev: #2
2.9
—
-154,000 -15.0%
P
S
870,000 $86,147,400 2025 Q3 13F Filing 2026-09-30 2026-11-16
CGON
CG ONCOLOGY INC
Healthcare 3.72% 3.06% #6 5
Prev: #11
2.0
—
-25,000 -2.5%
P
S
975,000 $69,117,750 2024 Q1 13F Filing 2026-09-30 2026-11-16
IRON
DISC MEDICINE I...
Healthcare 3.58% 2.76% #7 5
Prev: #12
3.4
—
140,000 16.0%
P
S
1,015,000 $66,441,900 2023 Q1 13F Filing 2026-09-30 2026-11-16
BNTX
BIONTECH SE
Healthcare 3.44% 4.07% #8 3
Prev: #5
1.4
—
-365,000 -36.0%
P
S
650,000 $63,895,000 2020 Q2 13F Filing 2026-09-30 2026-11-16
TNGX
TANGO THERAPEUT...
Healthcare 2.89% 3.84% #9 2
Prev: #7
1.2
—
-700,000 -24.6%
P
S
2,150,000 $53,642,500 2025 Q3 13F Filing 2026-09-30 2026-11-16
MDGL
MADRIGAL PHARMA...
Healthcare 2.71% — #10
Prev: #—
4.6
—
100,000 —
NEW
100,000 $50,396,000 2019 Q4 13F Filing 2026-09-30 2026-11-16
ELVN
ENLIVEN THERAPE...
Healthcare 2.67% 1.02% #11 21
Prev: #32
4.1
—
615,000 132.3%
P
S
1,080,000 $49,507,200 2023 Q1 13F Filing 2026-09-30 2026-11-16
DYN
DYNE THERAPEUTI...
Healthcare 2.60% 2.44% #12 2
Prev: #14
3.0
—
450,000 17.6%
P
S
3,000,000 $48,330,000 2020 Q3 13F Filing 2026-09-30 2026-11-16
OCUL
OCULAR THERAPEU...
Healthcare 2.48% 2.24% #13 3
Prev: #16
3.0
—
700,000 13.2%
P
S
6,000,000 $46,020,000 2023 Q4 13F Filing 2026-09-30 2026-11-16
DNTH
DIANTHUS THERAP...
Healthcare 2.37% 3.36% #14 4
Prev: #10
0.9
—
-300,000 -37.5%
P
S
500,000 $44,025,000 2025 Q3 13F Filing 2026-09-30 2026-11-16
AVBP
ARRIVENT BIOPHA...
Healthcare 2.20% 1.50% #15 8
Prev: #23
3.4
—
350,000 35.0%
P
S
1,350,000 $40,878,000 2026 Q1 13F Filing 2026-09-30 2026-11-16
COGT
COGENT BIOSCIEN...
Healthcare 2.16% 1.50% #16 6
Prev: #22
3.4
—
350,000 38.9%
P
S
1,250,000 $40,025,000 2020 Q4 13F Filing 2026-09-30 2026-11-16
ERAS
ERASCA INC
CALL
CALL Option 1.97% — #17
Prev: #—
4.3
—
2,500,000 —
NEW
2,500,000 $36,650,000 2024 Q2 13F Filing 2026-09-30 2026-11-16
NBIX
NEUROCRINE BIOS...
Healthcare 1.91% — #18
Prev: #—
4.3
—
250,000 —
NEW
250,000 $35,460,000 2022 Q1 13F Filing 2026-09-30 2026-11-16
BLTE
BELITE BIO INC
Healthcare 1.83% 1.66% #19
Prev: #19
0.7
—
-50,000 -20.0%
P
S
200,000 $33,964,000 2026 Q2 13F Filing 2026-09-30 2026-11-16
AXSM
AXSOME THERAPEU...
Healthcare 1.74% — #20
Prev: #—
4.2
—
175,000 —
NEW
175,000 $32,268,250 2019 Q4 13F Filing 2026-09-30 2026-11-16
GPCR
STRUCTURE THERA...
Healthcare 1.68% 1.16% #21 8
Prev: #29
3.7
—
500,000 100.0%
P
S
1,000,000 $31,270,000 2023 Q1 13F Filing 2026-09-30 2026-11-16
OLMA
OLEMA PHARMACEU...
Healthcare 1.49% 1.73% #22 4
Prev: #18
1.6
—
no change no change
P
S
3,208,875 $27,724,680 2020 Q4 13F Filing 2026-09-30 2026-11-16
ACHV
ACHIEVE LIFE SC...
Healthcare 1.39% 1.53% #23 3
Prev: #20
0.6
—
-2,225,000 -41.0%
P
S
3,200,000 $25,888,000 2026 Q2 13F Filing 2026-09-30 2026-11-16
MAZE
MAZE THERAPEUTI...
Healthcare 1.37% 2.49% #24 11
Prev: #13
0.5
—
-1,000,000 -51.7%
P
S
935,000 $25,413,300 2025 Q1 13F Filing 2026-09-30 2026-11-16
PBLS
PARABILIS MEDIC...
Healthcare 1.30% 0.62% #25 18
Prev: #43
3.0
—
225,000 42.9%
P
S
750,000 $24,217,500 2026 Q2 13F Filing 2026-09-30 2026-11-16
APMD
APNIMED INC
Healthcare 1.30% — #26
Prev: #—
4.0
—
1,100,000 —
NEW
1,100,000 $24,101,000 2026 Q3 13F Filing 2026-09-30 2026-11-16
YARW
YARROW BIOSCIEN...
Healthcare 1.25% — #27
Prev: #—
4.0
—
1,026,258 —
NEW
1,026,258 $23,111,330 2026 Q3 13F Filing 2026-09-30 2026-11-16
AVTX
AVALO THERAPEUT...
CALL
CALL Option 1.24% — #28
Prev: #—
4.0
—
1,500,000 —
NEW
1,500,000 $22,995,000 2024 Q3 13F Filing 2026-09-30 2026-11-16
TRVI
TREVI THERAPEUT...
Healthcare 1.11% 1.51% #29 8
Prev: #21
0.4
—
-435,000 -23.1%
P
S
1,445,000 $20,692,400 2024 Q1 13F Filing 2026-09-30 2026-11-16
MANE
VERADERMICS INC
Healthcare 1.11% 0.95% #30 3
Prev: #33
0.9
—
-10,000 -5.6%
P
S
170,000 $20,609,100 2026 Q1 13F Filing 2026-09-30 2026-11-16
REPL
REPLIMUNE GROUP...
CALL
CALL Option 1.07% — #31
Prev: #—
3.9
—
1,500,000 —
NEW
1,500,000 $19,860,000 2026 Q2 13F Filing 2026-09-30 2026-11-16
VERA
VERA THERAPEUTI...
Healthcare 1.04% 4.06% #32 26
Prev: #6
0.4
—
-1,600,000 -72.7%
P
S
600,000 $19,374,000 2021 Q4 13F Filing 2026-09-30 2026-11-16
DSGN
DESIGN THERAPEU...
CALL
CALL Option 1.02% — #33
Prev: #—
3.9
—
1,500,000 —
NEW
1,500,000 $18,855,000 2021 Q1 13F Filing 2026-09-30 2026-11-16
SRPT
SAREPTA THERAPE...
CALL
CALL Option 0.98% — #34
Prev: #—
3.9
—
1,000,000 —
NEW
1,000,000 $18,220,000 2019 Q4 13F Filing 2026-09-30 2026-11-16
SRPT
SAREPTA THERAPE...
Healthcare 0.98% — #35
Prev: #—
3.9
—
1,000,000 —
NEW
1,000,000 $18,220,000 2019 Q4 13F Filing 2026-09-30 2026-11-16
MLTX
MOONLAKE IMMUNO...
Healthcare 0.95% 2.24% #36 21
Prev: #15
0.4
—
-1,175,000 -43.9%
P
S
1,500,000 $17,550,000 2023 Q4 13F Filing 2026-09-30 2026-11-16
SMMT
SUMMIT THERAPEU...
CALL
CALL Option 0.91% — #37
Prev: #—
3.9
—
1,000,000 —
NEW
1,000,000 $16,910,000 2026 Q2 13F Filing 2026-09-30 2026-11-16
IMCR
IMMUNOCORE HLDG...
Healthcare 0.82% 0.82% #38 1
Prev: #37
0.8
—
-100,000 -16.7%
P
S
500,000 $15,145,000 2022 Q3 13F Filing 2026-09-30 2026-11-16
BHVN
BIOHAVEN LTD
Healthcare 0.79% — #39
Prev: #—
3.8
—
1,100,000 —
NEW
1,100,000 $14,685,000 2019 Q4 13F Filing 2026-09-30 2026-11-16
CRSP
CRISPR THERAPEU...
Healthcare 0.75% 0.70% #40 1
Prev: #41
0.8
—
-50,000 -16.7%
P
S
250,000 $13,830,000 2020 Q1 13F Filing 2026-09-30 2026-11-16
BHVN
BIOHAVEN LTD
CALL
CALL Option 0.72% — #41
Prev: #—
3.8
—
1,000,000 —
NEW
1,000,000 $13,350,000 2019 Q4 13F Filing 2026-09-30 2026-11-16
DFTX
DEFINIUM THERAP...
Healthcare 0.72% 0.16% #42 16
Prev: #58
3.3
—
270,000 337.5%
P
S
350,000 $13,321,000 2026 Q2 13F Filing 2026-09-30 2026-11-16
RCUS
ARCUS BIOSCIENC...
CALL
CALL Option 0.70% — #43
Prev: #—
3.8
—
500,000 —
NEW
500,000 $12,915,000 2023 Q2 13F Filing 2026-09-30 2026-11-16
ENTX
ENTERA BIO LTD
Healthcare 0.69% — #44
Prev: #—
3.8
—
4,411,764 —
NEW
4,411,764 $12,838,233 2026 Q3 13F Filing 2026-09-30 2026-11-16
DSGN
DESIGN THERAPEU...
Healthcare 0.68% 1.87% #45 28
Prev: #17
0.3
—
-2,000,000 -66.7%
P
S
1,000,000 $12,570,000 2021 Q1 13F Filing 2026-09-30 2026-11-16
CMPS
COMPASS PATHWAY...
CALL
CALL Option 0.67% — #46
Prev: #—
3.8
—
1,000,000 —
NEW
1,000,000 $12,440,000 2020 Q3 13F Filing 2026-09-30 2026-11-16
N/A
CRESCENT BIOPHA...
Unknown 0.67% 1.47% #47 23
Prev: #24
0.3
—
-1,050,000 -55.3%
P
S
850,000 $12,401,500 — 13F Filing 2026-09-30 2026-11-16
ETRA
ELECTRA THERAPE...
Healthcare 0.61% — #48
Prev: #—
3.7
—
1,000,000 —
NEW
1,000,000 $11,250,000 2026 Q3 13F Filing 2026-09-30 2026-11-16
NERV
MINERVA NEUROSC...
Healthcare 0.59% 0.79% #49 10
Prev: #39
1.2
—
no change no change
P
S
3,288,777 $11,017,403 2019 Q4 13F Filing 2026-09-30 2026-11-16
LBRX
LB PHARMACEUTIC...
Healthcare 0.52% 0.82% #50 12
Prev: #38
0.2
—
-335,000 -57.3%
P
S
250,000 $9,595,000 2025 Q3 13F Filing 2026-09-30 2026-11-16
Showing 1-50 of 96 holdings

Unlock Full Logos Global Management LP Analysis

PRO subscribers get access to all historical quarters, Excel/CSV exports, Portfolio Concentration Analytics (PCA), and Risk-Based ENB.

Full Historical Quarters
Excel & CSV Export
PCA & Risk-Based ENB
Auto Cost Basis
Position Change Alerts
Price-Held Analytics
Full history →